歌禮製藥(01672.HK)新冠口服抑制劑ASC10取得積極I期臨床結果
歌禮製藥-B(01672.HK)公布,新冠口服聚合(酉每)(RdRp)抑制劑ASC10在健康受試者中的多劑量遞增(MAD)I期研究取得積極頂線數據。
I期數據顯示,所有劑量的ASC10在中國受試者中安全性及耐受性良好。ASC10治療組和安慰劑治療組的安全性數據相似。
基於歌禮ASC10的I期結果以及莫諾拉韋在美國日本和中國患者中的臨床療效數據,ASC10註冊臨床試驗劑量選定為每次800毫克、每天兩次。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of this article is for reference only. It does not constitute an offer, solicitation, recommendation, opinion or guarantee of any securities, financial products or instruments.The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance.